Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CCL5 | P13501 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19731754 | 1.00 | HTR2A (0.37) | HTR2ACYP2D6HTR2CHTR7SIGMAR1 | |
| SCHEMBL19734482 | 0.83 | CCL5 (0.31) | SIGMAR1CCL5CCR5 | |
| SCHEMBL19734693 | 0.83 | CCR5 (0.38) | HTR2ACYP2D6HTR2CHTR7HTR6 | |
| SCHEMBL19731647 | 0.83 | CCL5 (0.31) | SIGMAR1CCL5CCR5 | |
| SCHEMBL19734729 | 0.81 | CCR5 (0.36) | HTR2ACYP2D6HTR2CHTR7CCL5 | |
| SCHEMBL19734481 | 0.78 | ESR1 (0.30) | — | |
| SCHEMBL19734479 | 0.78 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL24357829 | 0.78 | HTR2A (0.39) | HTR2ACYP2D6HTR2CHTR7HRH3 | |
| SCHEMBL29599495 | 0.78 | HTR2A (0.39) | HTR2ACYP2D6HTR2CHTR7HRH3 | |
| SCHEMBL28195957 | 0.77 | HTR2A (0.34) | HTR2ACYP2D6HTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017216280-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | HTR2A 41/4885CYP2D6 270/4885HTR2C 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.